Developer docs
API playgroundTry for free, no card

Search company profiles

Synbio Technologies

Full company profile

uuid00062un

Namestring
Synbio Technologies
Legal namestring
苏州泓迅生物科技股份有限公司
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou Industrial Park with a US operating entity; listed on China's NEEQ as 871854) operates an integrated synthetic biology Design-Build-Test-Learn (DBTL) platform serving academic researchers, biopharmaceutical developers, and industrial biotech customers across more than 20,000 global accounts. Its service portfolio is anchored by two flagship brands — Syno®C oligo/primer synthesis and Syno®GS gene synthesis — and extends into mRNA/RNA synthesis, a CRISPR gene editing platform with off-the-shelf and custom sgRNA libraries, viral packaging (lentivirus, AAV, adenovirus), multi-host recombinant protein expression (prokaryotic, yeast, baculovirus-insect, mammalian, cell-free), an antibody engineering platform, peptide services, sequencing and omics analysis (including a newly launched metabolomics service), and bioinformatics design tools. One-stop solutions layer on top of these for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening.

The company's technology stack includes proprietary NGCodon™ AI codon optimization (described as patented), chip-based Fragment XP DNA fragment synthesis, recombination-deficient host workflows for high-difficulty sequences (hairpins, long inverted repeats), and ProXpress point-of-use protein detection cards that compress synthesis-to-verification cycles. The commercial model combines quote-based custom professional services for enterprise biopharma with a catalogue of ready-made products (e.g., recombinant humanized collagen Pichia pastoris strains, CRISPR plasmids, recombinant proteins, Syno® adapters/blockers/hybrid capture probes). Distribution is hybrid: direct enterprise sales and self-serve LIMS ordering in China, a US operating entity, and a strategic global distribution partnership with VWR for worldwide reach. Strategic partnerships with Porton Biologics (CRDMO), BOE Sensor (hardware), and YanYin Technology (ecosystem) extend the platform's scope, and the company was recognized as a 2024 Jiangsu Province Specialized & Sophisticated SME.

Short descriptiontext

Synbio Technologies is a Suzhou-headquartered synthetic biology services company (founded 2013, listed on NEEQ 871854) operating an integrated DNA/RNA synthesis, CRISPR, viral packaging, and multi-host protein expression platform serving 20,000+ academic and biopharma customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonmouth Junction, United States
HQ citystring
Monmouth Junction
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene synthesis services, oligo synthesis services, recombinant protein expression, CRISPR gene editing services, viral vector packaging
Product category
Synthetic Biology Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Custom synthesis services
TypeProfessional Services
Description

Project-based revenue from custom gene synthesis, oligo synthesis, RNA synthesis, mRNA synthesis, peptide synthesis, gene library construction and CRISPR library customization, with service levels ranging from milligram to kilogram scale protein production. Pricing varies by complexity and length (e.g., "Second Generation Gene Synthesis" launched at promotional RMB 258 for <416bp).

synbio-tech.com.cn
2Catalogue product sales
TypeHardware Sales
Description

Direct sales of off-the-shelf products including CRISPR libraries (human, mouse, monkey, poultry, livestock, microbial), recombinant protein strains (humanized type I/III collagen Pichia pastoris strains, human fibronectin Pichia pastoris strain, human serum albumin strain, biosynthetic bilirubin, fluorescent modified bacterial strains), ProXpress protein rapid test cards, CRISPR plasmids (knockout vectors, high-throughput gene editing vector libraries), and oligos (monkeypox primer probe, CpG-ODN, Syno® Adapters/Blocker/Hybrid Capture Probe).

synbio-tech.com.cn
3Global distribution via VWR
TypeTransaction Fee
Description

Channel/distributor revenue stream through strategic distribution agreement with VWR (global laboratory products and services provider), extending reach to worldwide customers.

synbio-tech.com.cn
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Second Generation Gene Synthesis promotional offer
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Promotional price of RMB 258 for sequences under 416 bp, inclusive of upgraded gene synthesis flow plus rapid protein expression verification using JM109(DE3) direct cloning, auto-induction medium, and ProXpress protein detection card with COA report. Limited-time launch offer.

synbio-tech.com.cn
2Free trial of ProXpress rapid test cards
ModelFreemiumBilling cadencePay-as-you-go
Notes

Each product can be requested once (max two different products per laboratory); only 1 unit per product per lab. Products are free for scientific research use only — not for clinical diagnosis/treatment or food/drug applications. If ordered with a regular product order, shipping is free; standalone trial requests may incur a RMB 20 shipping fee.

synbio-tech.com.cn
3Custom service pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed for the bulk of the catalogue (oligos, genes, RNA, CRISPR libraries, proteins, peptides, viral packaging, sequencing, antibody services). Customers are directed to contact via phone 4000-973-630, email support@synbio-tech.com, online chat, or fill the online inquiry form to receive pricing.

synbio-tech.com.cn
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Syno®C
Description

Brand name for Synbio's DNA oligo / primer synthesis service line (常规引物合成, 超长引物合成, 修饰引物合成, 核酸探针合成, NGS引物合成, 简并引物合成, 核酸适配体合成, ASOs合成, Trimer引物合成, etc.).

synbio-tech.com.cn
+4 more records
Core offering1 text field

Synbio Technologies operates an integrated synthetic biology DBTL (Design-Build-Test-Learn) service platform delivering custom DNA/RNA synthesis, CRISPR gene editing, recombinant protein expression, antibody engineering, viral packaging, peptide synthesis, sequencing/omics, and bioinformatics. Its commercial catalogue includes ready-made CRISPR libraries, recombinant yeast/bacterial strains (e.g., humanized collagen Pichia pastoris strains, biosynthetic bilirubin), CRISPR plasmids, finished oligos, and ProXpress lateral-flow protein rapid detection cards. Revenue is generated through project-based custom services and direct catalogue product sales distributed globally via a VWR partnership.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Documented sgRNA library coverage >99% and uniformity <10 in mouse whole-genome CRISPR knockout case study
+4 more records
Product overview1 text field

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou with US operations) operates a multi-platform synthetic biology technology stack organized as a Design-Build-Test-Learn (DBTL) integrated solution. The portfolio is anchored by two flagship service brands — Syno®C primer/oligo synthesis and Syno®GS gene synthesis — and extends into complementary platforms: RNA/mRNA synthesis, the CRISPR gene editing platform with off-the-shelf CRISPR libraries, virus packaging (lentivirus/AAV/adenovirus), a multi-host recombinant protein expression platform, an antibody engineering platform, peptide services, sequencing & omics (including the newly launched metabolomics service), high-throughput DNA library construction, and bioinformatics analysis & design. On top of these services, the company layers one-stop solutions for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening. The commercial product catalogue includes ready-made synthetic biology strains (e.g., recombinant humanized collagen and serum albumin Pichia pastoris strains, MoClo-YTK modular yeast toolkit), CRISPR plasmids, recombinant proteins (Cas12, Protein A/G/L), finished oligos (Syno® adapters, blockers, hybrid capture probes), and the ProXpress point-of-use protein rapid test card line. AI capabilities (AI codon optimization via the proprietary NGCodon™ technology and AI-designed gene sequences) are embedded across the workflow.

Product and service1 record
1Syno®C Primer/Oligo Synthesis
CategoryOligonucleotide Synthesis Services
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Porton Biologics (博腾生物制药有限公司)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-06
Description

Signed a CRDMO strategic cooperation agreement on 6 May 2023 in Suzhou to establish a new partnership. Synbio Technologies provides synthetic biology design-build platforms while Porton Biologics contributes CRDMO capabilities for gene and cell therapy development.

synbio-tech.com.cn
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Synbio Technologies formally partnered with VWR, a global laboratory products and services giant, to enter VWR's distribution network. The partnership is positioned as a "global supply chain upgrade" enabling worldwide customers to access Synbio's molecular manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Signed a comprehensive strategic cooperation agreement at Synbio's Suzhou headquarters to deepen collaboration in synthetic biology. Signed by Synbio VP Qi Jincai (齐金才) and YanYin CEO Chen Zeping (陈泽平). Focuses on joint synthetic biology ecosystem innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Announced in March 2024 a deep strategic partnership with BOE Sensor to jointly explore new horizons in synthetic biology hardware equipment, leveraging a synthetic biology thinking framework. The collaboration targets innovation in upstream hardware used in synthetic biology workflows.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global life sciences giant offering gene synthesis (GeneArt), oligo synthesis, protein expression, CRISPR reagents, and viral vector services as part of a much broader portfolio. Overlaps with multiple Synbio platforms and serves the same enterprise biopharma customer base.

TypeDirect peer
Description

Synthetic biology company specializing in gene synthesis, protein engineering, and antibody optimization with an AI-driven codon optimization engine (similar positioning to NGCodon™). Directly comparable on gene synthesis and AI-optimized protein expression offerings.

TypeBroad incumbent
Description

Largest Chinese genomics company with broad DNA sequencing, synthesis, and synthetic biology capabilities. Comparable on gene synthesis, sequencing, and synthetic biology tooling, with significantly larger scale and brand recognition in China and globally.

TypeDirect peer
Description

Publicly traded leader in high-throughput silicon-based DNA synthesis and synthetic biology services, including gene fragments, genes, oligo pools, antibody libraries, and DNA data storage. Directly comparable on core gene/oligo synthesis offerings and similar academic/biopharma customer base, but at significantly larger scale.

TypeDirect peer
Description

Major US-based provider of custom oligonucleotides, gene synthesis, CRISPR reagents, and NGS services, owned by Danaher. Closest direct competitor to Synbio's Syno®C oligo and Syno®GS gene synthesis lines, with overlapping academic/biopharma customers.

TypeDirect peer
Description

Global biotech with gene synthesis, recombinant protein expression, antibody engineering, peptide, and cell therapy services. Directly overlaps with Synbio's multi-platform DBTL offering, and operates significant capacity in both US and China.

TypeDirect peer
Description

US-based synthetic biology company specializing in gene synthesis, sgRNA synthesis, and CRISPR genome editing tools. Highly comparable to Synbio's CRISPR platform and gene synthesis core, with similar academic/therapeutics customer focus.

TypeDirect peer
Description

Major Chinese synthetic biology and molecular biology services provider offering oligos, gene synthesis, protein expression, and CRISPR products. Headquartered in Shanghai and a primary China-based competitor to Synbio's full DBTL stack.

TypeDirect peer
Description

Leading Chinese DNA synthesis and synthetic biology services provider offering gene synthesis, oligo synthesis, gene editing, and protein expression. Closest direct domestic peer to Synbio in the China synthetic biology services market.

TypeDirect peer
Description

Global genomics services arm of Eurofins Scientific offering oligo synthesis, gene synthesis, DNA sequencing, and CRISPR services. Synbio lists Eurofins as a customer but Eurofins Genomics is also a direct competitor in synthesis services globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers50 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synbio Technologies

Synthetic Biology Servicessynbio-tech.com.cn

Synbio Technologies is a Suzhou-headquartered synthetic biology services company (founded 2013, listed on NEEQ 871854) operating an integrated DNA/RNA synthesis, CRISPR, viral packaging, and multi-host protein expression platform serving 20,000+ academic and biopharma customers globally.

What Synbio Technologies does

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou Industrial Park with a US operating entity; listed on China's NEEQ as 871854) operates an integrated synthetic biology Design-Build-Test-Learn (DBTL) platform serving academic researchers, biopharmaceutical developers, and industrial biotech customers across more than 20,000 global accounts. Its service portfolio is anchored by two flagship brands — Syno®C oligo/primer synthesis and Syno®GS gene synthesis — and extends into mRNA/RNA synthesis, a CRISPR gene editing platform with off-the-shelf and custom sgRNA libraries, viral packaging (lentivirus, AAV, adenovirus), multi-host recombinant protein expression (prokaryotic, yeast, baculovirus-insect, mammalian, cell-free), an antibody engineering platform, peptide services, sequencing and omics analysis (including a newly launched metabolomics service), and bioinformatics design tools. One-stop solutions layer on top of these for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening.

The company's technology stack includes proprietary NGCodon™ AI codon optimization (described as patented), chip-based Fragment XP DNA fragment synthesis, recombination-deficient host workflows for high-difficulty sequences (hairpins, long inverted repeats), and ProXpress point-of-use protein detection cards that compress synthesis-to-verification cycles. The commercial model combines quote-based custom professional services for enterprise biopharma with a catalogue of ready-made products (e.g., recombinant humanized collagen Pichia pastoris strains, CRISPR plasmids, recombinant proteins, Syno® adapters/blockers/hybrid capture probes). Distribution is hybrid: direct enterprise sales and self-serve LIMS ordering in China, a US operating entity, and a strategic global distribution partnership with VWR for worldwide reach. Strategic partnerships with Porton Biologics (CRDMO), BOE Sensor (hardware), and YanYin Technology (ecosystem) extend the platform's scope, and the company was recognized as a 2024 Jiangsu Province Specialized & Sophisticated SME.

Synbio Technologies firmographics

Firmographics
Name
Synbio Technologies
Legal name
苏州泓迅生物科技股份有限公司
Website
https://synbio-tech.com.cn
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Synbio Technologies is a Suzhou-headquartered synthetic biology services company (founded 2013, listed on NEEQ 871854) operating an integrated DNA/RNA synthesis, CRISPR, viral packaging, and multi-host protein expression platform serving 20,000+ academic and biopharma customers globally.
Ownership category
akta.pro rank

Where Synbio Technologies is headquartered

Location

Headquarters

HQ city
Monmouth Junction
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Synbio Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Custom synthesis services: Project-based revenue from custom gene synthesis, oligo synthesis, RNA synthesis, mRNA synthesis, peptide synthesis, gene library construction and CRISPR library customization, with service levels ranging from milligram to kilogram scale protein production. Pricing varies by complexity and length (e.g., "Second Generation Gene Synthesis" launched at promotional RMB 258 for <416bp).
  2. Catalogue product sales: Direct sales of off-the-shelf products including CRISPR libraries (human, mouse, monkey, poultry, livestock, microbial), recombinant protein strains (humanized type I/III collagen Pichia pastoris strains, human fibronectin Pichia pastoris strain, human serum albumin strain, biosynthetic bilirubin, fluorescent modified bacterial strains), ProXpress protein rapid test cards, CRISPR plasmids (knockout vectors, high-throughput gene editing vector libraries), and oligos (monkeypox primer probe, CpG-ODN, Syno® Adapters/Blocker/Hybrid Capture Probe).
  3. Global distribution via VWR: Channel/distributor revenue stream through strategic distribution agreement with VWR (global laboratory products and services provider), extending reach to worldwide customers.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseSecond Generation Gene Synthesis promotional offer
FreemiumPay-as-you-goFree trial of ProXpress rapid test cards
OtherPay-as-you-goCustom service pricing

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Synbio Technologies product offering

Product offering

Core offering

Synbio Technologies operates an integrated synthetic biology DBTL (Design-Build-Test-Learn) service platform delivering custom DNA/RNA synthesis, CRISPR gene editing, recombinant protein expression, antibody engineering, viral packaging, peptide synthesis, sequencing/omics, and bioinformatics. Its commercial catalogue includes ready-made CRISPR libraries, recombinant yeast/bacterial strains (e.g., humanized collagen Pichia pastoris strains, biosynthetic bilirubin), CRISPR plasmids, finished oligos, and ProXpress lateral-flow protein rapid detection cards. Revenue is generated through project-based custom services and direct catalogue product sales distributed globally via a VWR partnership.

Product overview

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou with US operations) operates a multi-platform synthetic biology technology stack organized as a Design-Build-Test-Learn (DBTL) integrated solution. The portfolio is anchored by two flagship service brands — Syno®C primer/oligo synthesis and Syno®GS gene synthesis — and extends into complementary platforms: RNA/mRNA synthesis, the CRISPR gene editing platform with off-the-shelf CRISPR libraries, virus packaging (lentivirus/AAV/adenovirus), a multi-host recombinant protein expression platform, an antibody engineering platform, peptide services, sequencing & omics (including the newly launched metabolomics service), high-throughput DNA library construction, and bioinformatics analysis & design. On top of these services, the company layers one-stop solutions for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening. The commercial product catalogue includes ready-made synthetic biology strains (e.g., recombinant humanized collagen and serum albumin Pichia pastoris strains, MoClo-YTK modular yeast toolkit), CRISPR plasmids, recombinant proteins (Cas12, Protein A/G/L), finished oligos (Syno® adapters, blockers, hybrid capture probes), and the ProXpress point-of-use protein rapid test card line. AI capabilities (AI codon optimization via the proprietary NGCodon™ technology and AI-designed gene sequences) are embedded across the workflow.

Differentiator

Problem solved

Functional benefit

Brands

  • Syno®C: Brand name for Synbio's DNA oligo / primer synthesis service line (常规引物合成, 超长引物合成, 修饰引物合成, 核酸探针合成, NGS引物合成, 简并引物合成, 核酸适配体合成, ASOs合成, Trimer引物合成, etc.).
  • Syno®GS
  • ProXpress
  • NGCodon™
  • Syno® Adapters / Syno® Blocker / Syno® Hybrid Capture Probe

Products and services

  • Syno®C Primer/Oligo Synthesis

Quantifiable outcome

  • Documented sgRNA library coverage >99% and uniformity <10 in mouse whole-genome CRISPR knockout case study
  • +4 more outcomes

Companies that use Synbio Technologies

Customer profile

Named customers50 records

Segments5 records

Ideal customer profiles4 records

Synbio Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Synbio Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Porton Biologics (博腾生物制药有限公司)coreStrategic or Co-development Partner · 6 May 2023Signed a CRDMO strategic cooperation agreement on 6 May 2023 in Suzhou to establish a new partnership. Synbio Technologies provides synthetic biology design-build platforms while Porton Biologics contributes CRDMO capabilities for gene and cell therapy development.
  • VWRflagshipChannel Partner/ Reseller/ DistributorSynbio Technologies formally partnered with VWR, a global laboratory products and services giant, to enter VWR's distribution network. The partnership is positioned as a "global supply chain upgrade" enabling worldwide customers to access Synbio's molecular manufacturing capabilities.
  • YanYin Technology (上海衍因科技有限公司)coreStrategic or Co-development PartnerSigned a comprehensive strategic cooperation agreement at Synbio's Suzhou headquarters to deepen collaboration in synthetic biology. Signed by Synbio VP Qi Jincai (齐金才) and YanYin CEO Chen Zeping (陈泽平). Focuses on joint synthetic biology ecosystem innovation.
  • BOE Sensor (北京京东方传感技术有限公司)coreStrategic or Co-development PartnerAnnounced in March 2024 a deep strategic partnership with BOE Sensor to jointly explore new horizons in synthetic biology hardware equipment, leveraging a synthetic biology thinking framework. The collaboration targets innovation in upstream hardware used in synthetic biology workflows.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Synbio Technologies competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific (GeneArt services): Global life sciences giant offering gene synthesis (GeneArt), oligo synthesis, protein expression, CRISPR reagents, and viral vector services as part of a much broader portfolio. Overlaps with multiple Synbio platforms and serves the same enterprise biopharma customer base.
  • BGI Genomics: Largest Chinese genomics company with broad DNA sequencing, synthesis, and synthetic biology capabilities. Comparable on gene synthesis, sequencing, and synthetic biology tooling, with significantly larger scale and brand recognition in China and globally.

Direct peers

  • ATUM (formerly DNA2.0): Synthetic biology company specializing in gene synthesis, protein engineering, and antibody optimization with an AI-driven codon optimization engine (similar positioning to NGCodon™). Directly comparable on gene synthesis and AI-optimized protein expression offerings.
  • Twist Bioscience: Publicly traded leader in high-throughput silicon-based DNA synthesis and synthetic biology services, including gene fragments, genes, oligo pools, antibody libraries, and DNA data storage. Directly comparable on core gene/oligo synthesis offerings and similar academic/biopharma customer base, but at significantly larger scale.
  • Integrated DNA Technologies (IDT): Major US-based provider of custom oligonucleotides, gene synthesis, CRISPR reagents, and NGS services, owned by Danaher. Closest direct competitor to Synbio's Syno®C oligo and Syno®GS gene synthesis lines, with overlapping academic/biopharma customers.
  • GenScript: Global biotech with gene synthesis, recombinant protein expression, antibody engineering, peptide, and cell therapy services. Directly overlaps with Synbio's multi-platform DBTL offering, and operates significant capacity in both US and China.
  • Synthego: US-based synthetic biology company specializing in gene synthesis, sgRNA synthesis, and CRISPR genome editing tools. Highly comparable to Synbio's CRISPR platform and gene synthesis core, with similar academic/therapeutics customer focus.
  • Sangon Biotech (Sangon): Major Chinese synthetic biology and molecular biology services provider offering oligos, gene synthesis, protein expression, and CRISPR products. Headquartered in Shanghai and a primary China-based competitor to Synbio's full DBTL stack.
  • Tsingke Biotechnology: Leading Chinese DNA synthesis and synthetic biology services provider offering gene synthesis, oligo synthesis, gene editing, and protein expression. Closest direct domestic peer to Synbio in the China synthetic biology services market.
  • Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering oligo synthesis, gene synthesis, DNA sequencing, and CRISPR services. Synbio lists Eurofins as a customer but Eurofins Genomics is also a direct competitor in synthesis services globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Synbio Technologies social profiles

Digital presence

Synbio Technologies compliance and trust

Trust signal

Compliance1 record

Synbio Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synbio Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Synbio Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synbio Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synbio Technologies

What does Synbio Technologies do?

Synbio Technologies operates an integrated synthetic biology DBTL (Design-Build-Test-Learn) service platform delivering custom DNA/RNA synthesis, CRISPR gene editing, recombinant protein expression, antibody engineering, viral packaging, peptide synthesis, sequencing/omics, and bioinformatics. Its commercial catalogue includes ready-made CRISPR libraries, recombinant yeast/bacterial strains (e.g., humanized collagen Pichia pastoris strains, biosynthetic bilirubin), CRISPR plasmids, finished oligos, and ProXpress lateral-flow protein rapid detection cards. Revenue is generated through project-based custom services and direct catalogue product sales distributed globally via a VWR partnership.

Is Synbio Technologies a public or private company?

Synbio Technologies is a private company. It is classified as public and is currently operating.

When was Synbio Technologies founded?

Synbio Technologies was founded in 2013. It employs 11 to 50 people.

Where is Synbio Technologies based?

Synbio Technologies is headquartered in Monmouth Junction, United States, in the North America region.

How does Synbio Technologies make money?

Three revenue lines are on record. Custom synthesis services are the primary driver. The others are catalogue product sales and global distribution via VWR.

Who are Synbio Technologies's main competitors?

Broad incumbents on record are Thermo Fisher Scientific (GeneArt services) and BGI Genomics. Direct peers are ATUM (formerly DNA2.0), Twist Bioscience, Integrated DNA Technologies (IDT), GenScript, Synthego, Sangon Biotech (Sangon), Tsingke Biotechnology and Eurofins Genomics.

Does Synbio Technologies have an API?

No public API is recorded for Synbio Technologies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSynthetic Biology Market Future Business Opportunities 2026-2033 | Thermo Fisher Scientific, Synbio Technologies, Merck KGaA, Agilent Technologies Inc.The article discusses the future prospects of the Synthetic Biology Market from 2026 to 2033, highlighting major companies involved such as Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies Inc. The report emphasizes regional trends, market segmentation, and strategic insights to guide decision-makers.openPR.comSynthetic Biology Market is evolving rapidly Through 2025 To 2032 | Thermo Fisher Scientific, Synbio TechnologiesThe synthetic biology market is projected to grow from USD 21.90 billion in 2025 to USD 90.73 billion by 2032, a CAGR of 22.5%. The forecast is based on a report by Coherent Market Insights, which also lists leading players and market segments.openPR.comUnexpected Trends Reshaping the Synthetic Biology Market by 2032 - What Industry Leaders Should Know | Thermo Fisher Scientific, Synbio TechnologiesThe global synthetic biology market is projected to grow from USD 21.90 billion in 2025 to USD 90.73 billion by 2032, a CAGR of 22.0%. Growth is driven by R&D investments, pharmaceutical adoption, and sustainable biofuel applications, with gene synthesis throughput rising over 30% year-over-year in 2024.openPR.comSynthetic Biology Market Deep Research Report with Forecast to 2032 | Thermo Fisher Scientific, Synbio TechnologiesThe synthetic biology market is projected to grow from USD 21.90 billion in 2025 to USD 90.73 billion by 2032, a CAGR of 22.5%. The report covers segmentation by product, technology, and end user, and lists key players including Thermo Fisher Scientific and Synbio Technologies.openPR.comSynthetic Biology Market Set to Witness Significant Growth by 2025-2032 | Thermo Fisher Scientific, Synbio Technologies, Merck KGaAThe synthetic biology market is projected to grow from USD 21.90 billion in 2025 to USD 90.73 billion by 2032, a CAGR of 22.5%. The forecast is based on a report by Coherent Market Insights, which also segments the market by product, technology, end user, and geography.openPR.comSynthetic Biology Market Surging with Biotech Innovations | Size, Share & Future Trends: Thermo Fisher Scientific, Synbio TechnologiesThe global synthetic biology market is projected to grow at a 22.3% CAGR from 2025 to 2032, according to a market research report by Coherent Market Insights. The report profiles key players including Thermo Fisher Scientific and Synbio Technologies, and covers segmentation by product, technology, and end user.Synbio-TechSynthetic Biology Company of Gene Synthesis SolutionSynbio Technologies is a synthetic biology company that provides custom gene synthesis, protein expression, and oligo synthesis services to researchers globally. The company supports over 20,000 customers with more than 200 researchers and has synthesized over 10 billion bases. Testimonials highlight the company's ability to deliver high-quality products for molecular biology research projects.